ASCO News In Brief: Immunomedics CEA-Scan
Executive Summary
Immunomedics CEA-Scan: Diagnostic imaging agent shows 92% specificity rate in predicting which breast lesions were not cancerous in patients with inconclusive mammography findings requiring surgical biopsies. Results of the 42-patient study were reported by Dutzu Rosner, MD, State University of New York, Buffalo. In an 84-patient colorectal cancer study, CEA-Scan correctly diagnosed disease in 36 (61%) of the 59 patients who had a previous CT-negative scan. CEA-Scan became "approvable" on April 9 and the company says it is awaiting FDA approval of product labeling...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth